Skip to main
COGT
COGT logo

Cogint (COGT) Stock Forecast & Price Target

Cogint (COGT) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences Inc. is projected to experience significant sales growth, with estimates reaching approximately $225 million by 2032 for the CGT9486 program, reflecting a robust 60% probability of success. Additionally, the company’s Bezuclastinib therapy shows a promising competitive profile compared to existing treatments, potentially capturing a meaningful market share in the advanced systemic mastocytosis space. The favorable early results from clinical trials, particularly the superior efficacy of CGT6297 in mouse models compared to existing therapies, further bolster the company's positive outlook by indicating strong potential for clinical success and market impact.

Bears say

Cogent Biosciences faces several significant risks impacting its financial outlook, including potential negative clinical data, slower-than-anticipated development timelines, and setbacks in regulatory approvals, all of which could hinder the advancement of key therapies. The company's lead candidate, bezuclastinib, may encounter challenges related to its safety profile, especially in non-advanced systemic mastocytosis, which could constrain its marketability and overall revenue potential. Additionally, the company has adjusted its projections for peak market penetration in the second-line gastrointestinal stromal tumor setting from 50% to 20%, reflecting a diminished confidence in achieving prior commercial success.

Cogint (COGT) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogint and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogint (COGT) Forecast

Analysts have given Cogint (COGT) a Buy based on their latest research and market trends.

According to 11 analysts, Cogint (COGT) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogint (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.